Achillion Pharmaceuticals, Inc. has entered into a global license and partnership agreement with Janssen Pharmaceuticals, Inc., of Johnson & Johnson, to market and advance the development of Achillion’s lead hepatitis C virus (HCV) holdings, including ACH-3102, ACH-3422, and sovaprevir.
The goal of the partnership is to develop an efficient pan-genotypic oral regimen for the treatment of HCV, for short-term use. A preliminary regimen to be considered features Achillion’s ACH-3102, taken in conjunction with an NS3/4A HCV protease inhibitor and an NS5B HCV polymerase inhibitor.
“We are excited to collaborate with Janssen for the worldwide development of our HCV assets in combination with their HCV portfolio. We believe that Janssen’s renowned expertise in HCV development and commercialization enables a synergistic opportunity to rapidly advance our combined HCV assets toward the market while simultaneously achieving an optimized treatment regimen for all HCV patients,” said Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion.